Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MBX Biosciences, Inc. (MBX : NSDQ)

• Company Description    MBX Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company's pipeline includes its lead product candidate MBX 2109, MBX 1416 and MBX 4291. MBX Biosciences Inc. is based in CARMEL, Ind. Number of Employees: 43

• Price / Volume Information    Yesterday's Closing Price: $12.40 Daily Weekly Monthly 20 Day Moving Average: 330,414 shares Shares Outstanding: 33.42 (millions) Market Capitalization: $414.46 (millions) Beta: 52 Week High: $27.50 52 Week Low: $4.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 15.67% 11.34% 12 Week 62.73% 36.88% Year To Date -32.72% -36.99%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11711 N. Meridian Street Suite 300 - Carmel,IN 46032 USA ph: 317-659-0200 fax: - investors@mbxbio.com https://mbxbio.com

• General Corporate Information    Officers P. Kent Hawryluk - Chief Executive Officer and President Richard Bartram - Chief Financial Officer Tiba Aynechi - Director James M. Cornelius - Director Carl Gordon - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 55287L101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 33.42 Most Recent Split Date: (:1) Beta: Market Capitalization: $414.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.64 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.73 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.76 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -51.06% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - 23.31 12/31/24 - 24.19 Quick Ratio 06/30/25 - - 03/31/25 - 23.31 12/31/24 - 24.19 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 7.04 12/31/24 - 7.70 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©